Clinical Trials Directory

Trials / Completed

CompletedNCT00320424

Hip Fracture Study of GSK576428 (Fondaparinux Sodium)

Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Hip Fracture Surgery

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
48 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

This study is requested by PMDA to confirm the efficacy and the safety for HFS.

Conditions

Interventions

TypeNameDescription
DRUGFondaparinux

Timeline

Start date
2006-02-16
Primary completion
2006-10-26
Completion
2006-10-26
First posted
2006-05-03
Last updated
2018-09-04
Results posted
2017-10-11

Source: ClinicalTrials.gov record NCT00320424. Inclusion in this directory is not an endorsement.

Hip Fracture Study of GSK576428 (Fondaparinux Sodium) (NCT00320424) · Clinical Trials Directory